Q-omics provides the consensus-scored ZNF800 profile across patient tissues and cancer cell-line models. ZNF800 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZNF800 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF800 protein abundance shows 21,751 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, THCA, and GBM as cancer lineages where ZNF800 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF800 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF800 survival associations across molecular data types. ZNF800 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF800 RNA expression–survival associations across cancer types. High ZNF800 expression shows unfavorable associations in CESC, UVM and LGG, but favorable associations in KIRC, LUAD and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify CESC as the clearest survival context for ZNF800 RNA expression.
This table summarizes ZNF800 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF800. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF800 shows lower tumor expression in THCA and higher tumor expression in KIRP, COAD, KIRC, CHOL and ESCA. The THCA box plot shows higher ZNF800 RNA expression in normal versus tumor tissue (log2 FC = −0.586, t-test p < 0.001).
This table shows molecular features associated with ZNF800 in patient tissues and cancer cell lines. In patient samples, ZNF800 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF800 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
